A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 2 Dose Regimens of Orally Administered SENS-111 (100 mg and 200 mg) Given During 4 Days in Patients Suffering From Acute Unilateral Vestibulopathy
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2018
At a glance
- Drugs SENS 111 (Primary)
- Indications Vertigo
- Focus Therapeutic Use
- Acronyms SENSORION
- Sponsors Sensorion
- 12 Apr 2018 According to a Sensorion media release, this trial has been authorized in Europe and South Korea in 2017 and recruitment is ongoing at these centers.
- 18 Oct 2017 According to a Sensorion media release, top-line data from this trial are expected towards the end of 2018.
- 29 Jun 2017 Planned End Date changed from 1 Apr 2019 to 1 Dec 2018.